Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 2506 AL 2520

Mechanistic role of boswellic acids in Alzheimer's disease: Emphasis on anti-inflammatory properties

Siddiqui A, Shah Z, Jahan RN, Othman I, Kumari Y.

Biomed Pharmacother. 2021 Dec;144:112250. doi: 10.1016/j.biopha.2021.112250. Epub 2021 Oct 1.

Inhibition of Histone Deacetylase 6 (HDAC6) as a therapeutic strategy for Alzheimer's disease: A review (2010-2020)

Li Y, Sang S, Ren W, Pei Y, Bian Y, Chen Y, Sun H.

Eur J Med Chem. 2021 Dec 15;226:113874. doi: 10.1016/j.ejmech.2021.113874. Epub 2021 Sep 27.

New trends in pharmacological control of neuropsychiatric symptoms of dementia

Scuteri D, Corasaniti MT, Tonin P, Nicotera P, Bagetta G.

Curr Opin Pharmacol. 2021 Dec;61:69-76. doi: 10.1016/j.coph.2021.09.002. Epub 2021 Oct 9.

The efficacy and safety of zolpidem and zopiclone to treat insomnia in Alzheimer's disease: a randomized, triple-blind, placebo-controlled trial

Louzada LL, Machado FV, Quintas JL, Ribeiro GA, Silva MV, Mendonça-Silva DL, Gonçalves BSB, Nóbrega OT, Camargos EF.

Neuropsychopharmacology. 2022 Jan;47(2):570-579. doi: 10.1038/s41386-021-01191-3. Epub 2021 Oct 11.

Exploring Aβ Proteotoxicity and Therapeutic Candidates Using Drosophila melanogaster

Elovsson G, Bergkvist L, Brorsson AC.

Int J Mol Sci. 2021 Sep 28;22(19):10448. doi: 10.3390/ijms221910448.

An Overview of Several Inhibitors for Alzheimer's Disease: Characterization and Failure

Boopathi S, Poma AB, Garduño-Juárez R.

Int J Mol Sci. 2021 Oct 6;22(19):10798. doi: 10.3390/ijms221910798.

[Neuroprotective treatment of tauopathies]

Respondek G, Krey L, Huber M, Pflugrad H, Wegner F, Höglinger GU.

Nervenarzt. 2021 Dec;92(12):1227-1238. doi: 10.1007/s00115-021-01210-0. Epub 2021 Oct 15.

Aduhelm: The Best Hope for Alzheimer's Disease Patients or the Worst Decision the FDA Has Ever Made?

Kurkinen M, Tran L.

J Alzheimers Dis. 2021;84(3):969-971. doi: 10.3233/JAD-215105.

AD Hypotheses and Suggested Clinical Trials

Mandal PK, Samkaria A, Maroon JC.

ACS Chem Neurosci. 2021 Nov 3;12(21):3968-3971. doi: 10.1021/acschemneuro.1c00627. Epub 2021 Oct 18.

Of education and public policy: Aducanumab

Lundebjerg NE, Hollmann PA, Supiano MA.

J Am Geriatr Soc. 2022 Jan;70(1):81-84. doi: 10.1111/jgs.17523. Epub 2021 Nov 3.

Ferulic Acid in Animal Models of Alzheimer's Disease: A Systematic Review of Preclinical Studies

Wang EJ, Wu MY, Lu JH.

Cells. 2021 Oct 5;10(10):2653. doi: 10.3390/cells10102653.

A geroscience motivated approach to treat Alzheimer's disease: Senolytics move to clinical trials

Gonzales MM, Krishnamurthy S, Garbarino V, Daeihagh AS, Gillispie GJ, Deep G, Craft S, Orr ME.

Mech Ageing Dev. 2021 Dec;200:111589. doi: 10.1016/j.mad.2021.111589. Epub 2021 Oct 21.

Secretases in Alzheimer's disease: Novel insights into proteolysis of APP and TREM2

Lichtenthaler SF, Tschirner SK, Steiner H.

Curr Opin Neurobiol. 2022 Feb;72:101-110. doi: 10.1016/j.conb.2021.09.003. Epub 2021 Oct 22.

FDA Drug Approval and the Ethics of Desperation

Largent EA, Peterson A, Lynch HF.

JAMA Intern Med. 2021 Dec 1;181(12):1555-1556. doi: 10.1001/jamainternmed.2021.6045.

Population pharmacokinetics and standard uptake value ratio of aducanumab, an amyloid plaque-removing agent, in patients with Alzheimer's disease

Kandadi Muralidharan K, Tong X, Kowalski KG, Rajagovindan R, Lin L, Budd Haberlain S, Nestorov I.

CPT Pharmacometrics Syst Pharmacol. 2022 Jan;11(1):7-19. doi: 10.1002/psp4.12728. Epub 2021 Oct 26.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias